Compare Figs Inc (FIGS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs ResMed Inc. — how do they compare? Figs Inc trades at $14.15 (market cap $2.37B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 13.8× Figs Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Figs Inc pays none. Which is the better fit depends on your goals.
| FIGS | RMD | |
|---|---|---|
Market Cap | $2.37B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $293.73 |
52-Week Low | $6.57 | $182.82 |
Enterprise Value | $2.13B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $14.50, up 0.76% today, with strong technical momentum and bullish moving averages. Recent Q2 2026 earnings beat expectations with $0.11 EPS and 29% revenue growth, leading to a raised 2026 outlook. The company maintains a high gross margin of 68.91% but faces valuation concerns with a P/E of 43.24. Analyst sentiment is positive with a $19.50 consensus price target.
Outlook remains favorable due to accelerating revenue growth and margin expansion, though the rich valuation and execution risks in H2 2026 pose challenges. Institutional buying and a $100 million share buyback program support bullish sentiment, but investors should weigh premium multiples against growth sustainability.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
